| Literature DB >> 34876008 |
Xi Wang1, Fei Chen1, Tian-Yuan Xiong1, Yi-Jian Li1, Yuan-Weixiang Ou1, Qiao Li1, Yong Peng1, Jia-Fu Wei1, Sen He1, Mao Chen1, Yuan Feng2.
Abstract
BACKGROUND: Optimal projection is essential for valve deployment during transcatheter aortic valve implantation (TAVI). The purpose of this study was to propose an approach to predict optimal projection in TAVI candidates with different aortic valve anatomies.Entities:
Keywords: Bicuspid aortic valve; MSCT; Optimal projection; TAVI
Mesh:
Year: 2021 PMID: 34876008 PMCID: PMC8650525 DOI: 10.1186/s12872-021-02387-7
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1The non-coronary cusp-parallel technique to predict optimal projection during transcatheter aortic valve implantation. a After identifying the native annulus, the S-curve of the annulus would be generated by FluoroCT software, on which the annulus would always be aligned. Then one plane parallel to the annulus where all commissures could be clearly observed would be chosen to determine the non-coronary cusp (NCC) -parallel view. The S-curve is tracked until the red line (sagittal plane) connects the R-N commissure and L-N commissure on the determined transverse plane, showing the NCC-parallel view as right anterior oblique (RAO) 25 and caudal (CAU) 23. b As for type 0 bicuspid aortic valve patients, commissures between the two cusps would be connected by the red line when tracking the annulus S-curve, showing the NCC-parallel view as RAO 29 and CAU 32
Characteristics of the study population
| All (n = 331) | TAV (n = 206) | BAV (n = 125) | P value | |
|---|---|---|---|---|
| Age, years | 73.61 ± 7.35 | 74.54 ± 7.33 | 72.09 ± 7.17 | 0.003 |
| Male, % (n) | 59.8 (198) | 62.6 (129) | 55.2 (69) | 0.18 |
| Body Mass Index, kg/m2 | 22.88 ± 3.60 | 22.71 ± 3.70 | 23.16 ± 3.43 | 0.28 |
| NYHA III-IV, % (n) | 62.5 (207) | 60.2 (124) | 66.4 (83) | 0.26 |
| LVEF < 50%, % (n) | 37.5 (124) | 36.9 (76) | 38.4 (48) | 0.78 |
| STS score, % | 5.09 ± 5.12 | 5.36 ± 5.73 | 4.65 ± 3.91 | 0.23 |
| Aortic valve calcium volume, mm3 | 525.30 ± 508.45 | 362.16 ± 371.76 | 730.81 ± 580.64 | < 0.001 |
| Comorbidities, % (n) | ||||
| Hypertension | 49.5 (164) | 52.4 (108) | 44.8 (56) | 0.18 |
| Diabetes | 19.9 (66) | 18.4 (38) | 22.4 (28) | 0.38 |
| Coronary artery disease | 22.4 (74) | 22.8 (47) | 21.6 (27) | 0.80 |
| Prior myocardial infarction | 1.8 (6) | 2.4 (5) | 0.8 (1) | 0.52 |
| Prior stroke | 4.5 (15) | 3.9 (8) | 5.6 (7) | 0.47 |
| COPD | 11.8 (39) | 14.6 (30) | 7.2 (9) | 0.04 |
| Chronic kidney disease | 6.9 (23) | 6.8 (14) | 7.2 (9) | 0.89 |
| Atrial fibrillation | 18.7 (62) | 21.8 (45) | 13.6 (17) | 0.06 |
| Prior pacemaker | 3.0 (10) | 3.9 (8) | 1.6 (2) | 0.40 |
NYHA New York Heart Association, LVEF left ventricular ejection fraction, STS The Society of Thoracic Surgeons, COPD chronic obstructive pulmonary disease
Fig. 2Comparison of NCC-parallel view and final implanted view. The NCC-parallel view and final implanted view could most often be obtained in the RAO/CAU quadrant for both TAVs and BAVs (type 0 subtype 2 BAVs were excluded). There was less than 5° change required from NCC-parallel view to the final implanted view in 79% of TAV patients and 62.3% of BAV patients. BAV, bicuspid aortic valve; CAU, caudal; CRA, cranial; LAO, left anterior oblique; NCC, non-coronary cusp; RAO, right anterior oblique; TAV, tricuspid aortic valve
Fig. 3Different predicted views and the final implanted view. The conventional 3-cusp co-planar view (RAO8 CAU8) (a), cusp-overlap view (RAO34 CAU29) (b) and NCC-parallel view (RAO25 CAU23) (c) in one patient. THV was deployed in the NCC-parallel view (d) and there was no parallax of the delivery catheter as the three radiopaque markers on the catheter were in plane. CAU, caudal; LCC, left coronary cusp; NCC, non-coronary cusp; RAO, right anterior oblique; RCC, right coronary cusp; THV, transcatheter aortic valve
Procedural outcomes of the study population
| Procedural outcomes, %(n) | All(n = 331) | TAV(n = 206) | BAV(n = 125) |
|---|---|---|---|
| Successful THV implantation | 100 (331) | 100 (206) | 100 (125) |
| Major vascular complication | 2 (7) | 2.4 (5) | 1.6 (2) |
| Major bleeding | 1.2 (4) | 0.5 (1) | 2.4 (3) |
| New onset permanent pacemaker | 24.8 (82) | 27.2 (56) | 20.8 (26) |
| In-hospital stroke | 0.3 (1) | 0.5 (1) | 0 |
| Moderate or severe paravalvular leak | 0.6 (2) | 0.5 (1) | 0.8 (1) |
THV transcatheter heart valve